Chronic kidney disease (CKD)
When treating anemia in CKD patients not on dialysis
divider
Expected rise in hemoglobin (Hb) starting
at Week 41,2*
Expected rise in hemoglobin (Hb) starting at Week 4
Study design
Based on a prospective, interventional study in 56 patients not on dialysis receiving initiation doses of 50 U/kg to 100 U/kg TIW. Mean change in Hb values based on 50 U/kg and 100 U/kg; does not include 150 U/kg dosing.1,3

  • Results demonstrated a >1.0 g/dL mean increase in Hb in 4 weeks and a >2.0 g/dL mean increase in 8 weeks1,3
  • These Hb increases were calculated from the hematocrit (HCT) increases, assuming an HCT:Hb conversion rate of 3:14
*Week 4: 50 U/kg (n=27); 100 U/kg (n=25).3
 Week 8: 50 U/kg (n=27); 100 U/kg (n=24).3
divider
Selected safety profile
Adverse reactions occurring in ≥5% of adult patients5†

Adverse reaction PROCRIT®-treated patients (n=131) Placebo-treated patients (n=79)
Hypertension 13.7% 10.1%
Arthralgia 12.2% 7.6%
  • From 2 double–blind, placebo–controlled studies in 210 patients with CKD not on dialysis5
†Adverse reactions with a reported incidence of ≥5% in patients treated with PROCRIT® that occurred at ≥1% higher frequency than in placebo–treated patients.5
divider

References
  1. The US Recombinant Human Erythropoietin Predialysis Study Group. Double–blind, placebo–controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis. 1991;18:50–59.
  2. Abels R. Rate of progression of chronic renal failure in predialysis patients treated with erythropoietin. Semin Nephrol. 1990;10(suppl 1):20–25.
  3. Data on file. Janssen Products, LP.
  4. Kawthalkar SM. Essentials of Haematology. 2nd ed. New Delhi, India: Jaypee Brothers Medical Publishers (P) Ltd; 2013.
  5. PROCRIT® (epoetin alfa) Prescribing Information. Janssen Products, LP.
 
INDICATIONS
Expand ISI
IMPORTANT SAFETY INFORMATION
Expand ISI